Work

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Year: 2022

Type: article

Study design: Observational Study

Source: Blood

DOI: 10.1182/blood-2022-163485

Authors: Naseema Gangat, Rimal Ilyas, Kristen McCullough, Kebede H. Begna, Aref Al-Kali, Mrinal M.M. Patnaik, Mark R. Litzow, William J. Hogan, Abhishek A. Mangaonkar, Hassan B. Alkhateeb, Mithun V. Shah, Michelle A Elliott, James M. Foran, Talha Badar, Jeanne M. Palmer, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi

Institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic in Arizona, Mayo Clinic Hospital

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310099670

FWCI: 0.717

Cites:

Cited by: 5

Related to: 10